Axsome Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
21analysts covering
FY Revenue (est.)
$971Mnext fiscal year
FY EPS (est.)
-$2.64next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 6 Nov 2026 |
Monitoring Framework
Key Performance Indicators
AUVELITY Net Product Revenue Quarterly153.2MTarget: At least $8 billion in peak annual sales (combined MDD and Alzheimer's disease agitation)
SUNOSI Net Product Revenue Quarterly33.9MTarget: $1 billion to $3 billion in peak sales (including ADHD and other pipeline indications)
SYMBRAVO Net Product Revenue Quarterly4.1MTarget: Continued commercial ramp following June 2025 launch
Total Net Product Revenue Quarterly191.2M
Watch Items
- Commercial Launch of AUVELITY for Alzheimer's Disease Agitation (ADA)Trigger: June 2026 launch execution and sales force expansion to ~630 representativesAction: Monitor initial prescription uptake, community vs. long-term care split, and Medicare Part D coverage expansion.
- Regulatory Progress of AXS-12 for Cataplexy in NarcolepsyTrigger: NDA submission completed to the FDAAction: Track FDA acceptance of the NDA filing, potential PDUFA date assignment, and pre-launch commercial preparation.
- Phase 3 Pipeline Readouts for Solriamfetol (SUNOSI)Trigger: Topline results from the ENGAGE Phase 3 trial in Binge Eating Disorder (BED) in H2 2026Action: Evaluate clinical efficacy and safety data to support label expansion and peak sales targets of $1B-$3B.
Research as of 2 Sep 2026